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OnabotulinumtoxinA (OnabotA) was approved for treatment of chronic migraine (CM) after publication of PREEMPT
trials. Thus, we set out to evaluate the efficacy of OnabotA in a series of patients with CM treated according to the
PREEMPT protocol.
In May 2012 we began to offer OnabotA to patients with CM who did not respond to topiramate and at least one
other preventive therapy (beta blocker and/or calcium channel antagonist). We prospectively recorded demographic
data and the characteristics of migraine, and we assessed the modifications in monthly headache and migraine days, as
well as the number of days of symptomatic medication and triptan intake.
By September 2014 we had treated 52 patients (8 male, 44 female), whose age at treatment onset was 42.8 ± 12.7 years
(range: 16–71) and age at migraine onset was 16.8 ± 7.8 years (3–32). In 43 of these patients (82.7%) symptomatic
overuse of medication was observed at the onset of treatment. A total of 168 procedures were performed and
after the first session, we observed a significant reduction in all the variables considered. Twelve (23.1%) patients
failed to perceive a positive effect after the first procedure and it was not repeated in 4 of them. By contrast, there
was a significant decreasing in all the variables evaluated compared to the baseline in the 39 patients that received a
second series of injections.
The use of OnabotA according to the PREEMPT paradigm is an effective treatment in patients with chronic migraine in
a real-life setting.
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Chronic migraine (CM) is a common and disabling
condition affecting up to 2.4% of the population
(Manack et al. 2011; Natoli et al. 2010). CM was recog-
nized as an independent entity in the third edition of
the International Classification of Headache Disorders
(ICHD-III), where it was defined as persistent headache
on ≥ 15 days per month for ≥ 3 months; the criteria
for migraine were met or the headache responded
to migraine-specific treatment on ≥ 8 days (Headache
Classification Committee of the International Headache
Society (IHS) 2013).* Correspondence: gueneurol@gmail.com
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in any medium, provided the original work is pRisk factors for the chronification of migraine have
been identified, such as female gender, older age,
Caucasian ethnicity, low socio-economic status, co-
morbidity with other chronic diseases like obesity or
psychiatric disorders, high frequency episodic migraine
and overuse of symptomatic medication (Natoli et al.
2010; Rojo et al. 2015).
After publication of the PREEMPT clinical study
(Aurora et al. 2010; Diener et al. 2010; Dodick et al.
2010), in January 2012 OnabotulinumtoxinA (OnabotA)
was licensed in Spain for prophylactic treatment of CM
“for patients who have not adequately responded or are
intolerant to prophylactic drugs for migraine”.
Our objective was to analyze the efficacy of OnabotA
in treating CM in our population following the infiltrationan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Migraine characteristics at inclusion in the 52
patients
Variable
Overuse of symptomatic medication 43/52 (82.7%)
- Analgesics 31/52 (59.6%)
- Combined medications 12/52 (23.1%)
Previous use of neuromodulators 52/52 (100%)
- Topiramate 48/52 (92.3%)
- Other 26/52 (50%)
Previous use of beta-blockers 46/52 (88.5%)
Previous use of Calcium channel antagonists 33/52 (63.5%)
Previous use of antidepressants 30/52 (57.7%)
Previous use of anaesthetic blockades 11/52 (21.1%)
Monthly headache days 23.4 ± 6.3 (15–30)*
Monthly migraine days 13.9 ± 7.3 (8–30)*
Monthly symptomatic medication intake days 17.7 ± 9.2 (3–30)*
Monthly triptan intake days 5.1 ± 6.9 (0–25)*
Monthly visits to emergency department 0.25 ± 0.9 (0–6)*
*mean ± standard deviation (range).
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et al. 2010) in a real clinical setting.
Methods
From May 2012, OnabotA was offered to adult patients
with CM (revised ICHD-II criteria) (Olessen et al. 2006)
who attended a headache outpatient clinic at a tertiary
hospital. We included patients who experienced a sig-
nificant disruption in their quality of life, and who had
not responded positively to previous treatment with
topiramate (or another neuromodulator if topiramate
was not tolerated) and at least one other preventative
therapy (beta blocker and/or calcium channel antagon-
ist), ensuring that all these drugs had been administered
at adequate doses and for sufficient time to have been
effective (Levin 2008; Schulman et al. 2008). In cases
with tenderness to palpation of the pericranial nerves
(occipital or supraorbital), at least one anaesthetic block-
ade was performed with no effect.
We collected the demographic data and the migraine
characteristics from all the patients. We did not exclude
patients that fulfilled the criteria for overuse of medica-
tion, nor those receiving any preventive therapy, as it
was our aim that our cohort would reflect a real clinical
setting as closely as possible.
After having decided to initiate OnabotA therapy,
patients were trained during one month to complete a
diary where they recorded information on their head-
ache days, migraine days (defined as high intensity, later-
alized pain with a strong repercussion on daily activities)
and the number of days on which they took acute
headache medication, in particular triptans, as well as
the number of visits to the emergency department as
a consequence of headache. Three months after each
treatment session, we considered how each variable
collected in the diary had been modified. In all cases,
OnabotA was administered according to the PREEMPT
(Blumenfeld et al. 2010) protocol, performing no add-
itional injections in the first two treatment sessions.
We also asked patients to express their subjective con-
sideration of the efficacy after each session (excellent,
good, partial or no effect).
Statistical analysis was performed with the SPSS
statistical package (version 20.0 Inc., Chicago, IL, USA),
and any possible association between the baseline
migraine data and those recorded after each treatment
was assessed using a Student’s t-test.
Results
By September 2014 we had treated 52 CM patients
(8 male, 44 female) with OnabotA according to the
PREEMPT protocol. The mean age of this cohort at
migraine onset was 16.8 ± 7.8 years (range 3–32) and
the mean age at treatment onset was 42.8 ± 12.7 years(16–71). At inclusion, 43 cases (82.7%) fulfilled the
revised ICHD-II criteria for symptomatic overuse of
medication (Olessen et al. 2006) and 44 (84.6%) were
receiving preventive therapy. The migraine character-
istics of these 52 patients are shown in Table 1.
The response to the first session of treatment in these
52 cases is shown in Table 2. Following treatment, there
was a reduction of between 46.5 and 58.1% in the
number of headache days, migraine days and days of
acute medication or triptan intake. Indeed, the propor-
tion of patients that experienced a reduction of at least
50% in any of these variables ranged between 57.6 and
74%. The parameter that diminished in the largest
number of patients was the number of days of triptan
intake. In all cases the differences were statistically
significant (p ≤ 0.05).
There were 12 patients (23.1%) who perceived a lack
of efficacy after the first treatment cycle and although
we encouraged them to accept a second treatment, four
of them refused.
In total, 168 treatment cycles were administered and
performing a second set of injections on 39 patients pro-
duced a significant reduction in all the variables assessed
compared to the baseline (Table 3). The reduction in the
number of days with pain or migraine, and in acute
medication or triptan intake ranged between 36.3 and
73.1%. Moreover, the proportion of patients in whom
the reduction was at least 50% in any of these parame-
ters oscillated between 57.9 and 74.3%. These differences
were statistically significant for all the variables mea-
sured, although the greatest reduction after the second
Table 2 Changes in the variables evaluated after first treatment cycle (n = 52 patients)
Variable Before treatment After treatment P Reduction Reduction ≥ 50%
Headache days 23.4 ± 6.3* 12.8 ± 9.6* <0.001 46.5% 30/52 (57.6%)
Migraine days 13.9 ± 7.3* 5.3 ± 5.5* <0.001 52.9% 34/52 (65.3%)
Medication intake days 17.7 ± 9.2* 8.7 ± 8* <0.001 50.4% 31/52 (59.6%)
Triptan intake days 5.1 ± 6.9* 2.1 ± 3.6* <0.001 58.1% 20/27 (74%)
*mean ± standard deviation (range).
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of migraine days.
In no case was the treatment discontinued due to
adverse effects.
Discussion
Chronic migraine is diagnosed in 5% of patients that are
referred to a general neurology department (Oterino
et al. 2011) and globally, migraine is currently consid-
ered the seventh most influential disabling condition
according to World Health Organization (Steiner et al.
2013). It is a condition that has an important negative
impact on the life of an individual, particularly in terms
of family and social interactions, as well as at the eco-
nomic or occupational levels. Indeed, CM is associated
with a substantial reduction in quality of life.
Though CM requires preventive therapy, only 33.3%
of the patients referred to a headache unit had previ-
ously received such treatment (Mathew & Jaffri 2009).
Topiramate is the only drug among the medications
used in episodic migraine prophylaxis for which benefits
in the treatment of CM have been established (Cady
et al. 2011; Palma et al. 2012). However, up to 5% of CM
patients attending a Headache unit are refractory to oral
therapies (Aurora et al. 2011), and this group of patients
includes those that are more disabled and that have a
worse quality of life.
The PREEMPT (Phase III REsearch Evaluating Migraine
Prophylaxis Therapy) clinical study was a multicenter,
double-blind and placebo-controlled trial carried out in
two phases. This study demonstrated the efficacy, safety
and tolerability of OnabotA as a prophylactic treatment
for CM in adults (Aurora et al. 2010; Diener et al. 2010;
Dodick et al. 2010; Blumenfeld et al. 2010). However,
the mechanisms by which OnabotA decreases theTable 3 Changes in the variables evaluated between the base
(n = 39 patients)
Variable Before treatment After treatm
Headache days 23.8 ± 6.9* 9.2 ± 9.8*
Migraine days 14.7 ± 7.6* 3.9 ± 6.4*
Medication intake days 18.9 ± 9* 7.4 ± 8.2*
Triptan intake days 5.4 ± 7.3* 2.3 ± 3.7*
*mean ± standard deviation (range).frequency and intensity of pain attacks in CM patients
are not well understood.
In our series of patients, CM refractory to oral pre-
ventative therapies is more frequent among females,
with an onset of episodic migraine around the second
decade of life and a need for OnabotA therapy in the
beginning of fifth decade. These data are similar to those
described previously and they show that there may be a
long latency period between the onset of migraine and
the need for OnabotA therapy. This could indicate that
CM is in some cases part of the natural evolution of
episodic migraine (Álvaro-González et al. 2012), for which
there is currently no conclusive evidence regarding the
efficacy of treatment with OnabotA (Aurora et al. 2007;
Relja et al. 2007).
The baseline situation of the patients in our series was
similar to that described in the PREEMPT (Dodick et al.
2010) trial, as well as that in recently published observa-
tional studies (Palma et al. 2012; Álvaro-González et al.
2012; Silberstein et al. 2013). We considered oral pre-
ventative refractoriness as an inclusion criteria, including
the failure of topiramate therapy (or other neuromodu-
lators if topiramate is not tolerated) and at least one
other preventative therapy (beta blockers and/or calcium
channel antagonists). Indeed, new consensus criteria has
included refractoriness to OnabotulinumtoxinA among
the chronic migraine criteria (Martelletti et al. 2014).
In this study we present data regarding the response
to a first cycle of OnabotA therapy, a situation rarely
considered in the literature, especially when employing
the PREEMPT paradigm (Álvaro-González et al. 2012).
Our results are more homogeneous as we did not
administer the remaining 40 IU to the additional areas
where pain was experienced as considered in the first two
treatment sessions of the PREEMPT protocol. Rather, weline and three months after the second treatment cycle
ent P Reduction Reduction ≥ 50%
<0.001 62% 27/39 (69.2%)
<0.001 73.1% 29/39 (74.3%)
<0.001 57.7% 28/39 (71.8%)
<0.001 36.3% 11/19 (57.9%)
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response time was shorter than three months after
second session.
The response rate was considered as the reduction of
headache days, as in the PREEMPT clinical program
(at least half of them (Dodick et al. 2010)), and it is
above 50%. As described in other series, greater reduc-
tions are achieved in the number of migraine days and
the number of days of triptans intake (Aurora et al.
2010; Oterino et al. 2011; Lipton et al. 2011). In our
series, the subjective evaluation of efficacy referred to by
the patients was between excellent and partial in most of
them. These responses imply an important improvement
in quality of life, as noted previously in the literature
(Khalil et al. 2014; Batty et al. 2013).
The safety and tolerability of OnabotA was excellent
in our population, with only mild pain at the injection
site reported in some cases, and a mild dysphagia in one
female patient with a low body mass index, which did
not recur after the 4 paracervical injections were ex-
cluded in the following cycle. Therefore, as described in
both the PREEMPT trial and in open studies, adverse
effects of OnabotA in CM are scarce and reversible
(Aurora et al. 2010; Blumenfeld et al. 2010; Álvaro-
González et al. 2012; Aurora et al. 2007).
Health service approval of OnabotA as a prophylactic
treatment for CM has allowed us to offer this therapy to
our patients, although as with any new indication, clini-
cians must remain vigilant about its safety and efficacy
(Jackson et al. 2012). Further studies are needed to answer
some questions that remain open, such as the existence of
response predictors (including biomarkers), the manage-
ment of concomitant oral preventative therapies, or the
possible need to modify the OnabotA paradigm depending
on the type of response, only partial or good and sustained.
Conclusion
In conclusion, when used according to the PREEMPT
paradigm OnabotA is a safe and effective treatment in a
real clinical setting, even when criteria of refractoriness
to oral preventatives exist.
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